ATM positive

This Quality Initiative to improve testing and identification of HRR mutations in patients with mCRPC led to a 33% relative increase in HRR testing, demonstrating how QI programs can transform care and move the field toward individualized, precision medicine.

P2, N=229, Completed, Bayer | Recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2023

P2, N=202, Terminated, Pfizer | Active, not recruiting --> Terminated; The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)

Our results demonstrated the unique clinical and molecular features of pathogenic ATM/ATR mutations in NSCLC, which helps better understand the cancerous involvement of these DDR regulators, as well as directing targeted therapies and/or immunotherapies to treat ATM/ATR-mutated NSCLC patients, especially those with co-existing FA/HR aberrations.

P2, N=239, Recruiting, Bayer | Trial completion date: Apr 2024 --> Apr 2025

The aTMTV algorithm demonstrated good performance for the measurement of TMTV in patients with non-Hodgkin lymphoma, while showing good generalizability across lymphoma subtypes, patient subpopulations and PET/CT scanner manufacturers. Reduced algorithm performance for small lesions (≤ 10 mL) may be the result of higher variability among readers in the determination of small lesions; future work aims to refine and optimize performance of the algorithm for use as a prognostic tool in clinical practice. Artificial intelligence, Lymphoma, Tumor, FDG-PET

He underwent 6 cycles of palliative chemotherapy with carboplatin and Taxol for carcinoma of unknown origin...He received suppressive dose levothyroxine...For rectal cancer, he received radiation therapy and capecitabine.Our case is interesting for several reasons...Combination therapy with Lenvatinib and Pembrolizumab is currently under trial for aggressive thyroid malignancy...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

This quality initiative to improve testing and identification of HRR mutations in patients with mCRPC led to a 33% relative increase in HRR testing. Quality initiative programs are critical to transforming cancer care and moving the field closer toward individualized, precision medicine.

This real-world study shows an opportunity to increase rates of PARPi treatment in patients with HRRm mCRPC across all HRR gene mutations. mCRPC patients with BRCA and ATM mutations were more likely to receive PARPi than those with other HRR mutations.

Notably, while we saw strong familial patterns in MPN families, germline testing did not always detect a hereditary component; 8/9 patients with a first-degree family history of MPN had no actionable variants. While the hereditary nature of MPNs should be considered in clinical analysis, larger cohort studies are needed to determine stronger clinical markers of germline inheritance.

Thus, this study suggests a new angle of ATM mutations in MCL pathogenesis which could improve risk stratification. Overall, this study may unravel distinct mechanisms of tumorigenesis with relevant clinical and biological implications.

In the oxaliplatin-treated subset, PV carriers showed better control of the disease, although this was not statistically significant (67% vs. 56%)...ATM PVs were positively associated with OS in 41% of PV carriers, 60% of whom carried CDKN2A,BRCA2 or ATM PVs, had negative FH and would have been missed by traditional referral. Thus, CDKN2A and ATM should be added to BRCA1/2 testing regardless of FH.

P2, N=239, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting

The present study demonstrated that ATM-AS, an antisense transcript located within the ATM gene body, is an essential positive regulator of ATM expression, and functions by mediating the binding of KAT5 to the ATM promoter. These findings uncover the novel mechanism underlying the dysregulation of the ATM gene in breast cancer, and enrich our understanding of how an antisense transcript regulates its host gene.

P2, N=239, Recruiting, Bayer | Active, not recruiting --> Recruiting

P2, N=241, Active, not recruiting, Bayer | Trial primary completion date: Apr 2024 --> Dec 2022

P2, N=241, Active, not recruiting, Bayer | Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Apr 2024

P2, N=241, Active, not recruiting, Bayer | Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Aug 2023

P2, N=241, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting

P2, N=165, Ongoing, IMPACT Therapeutics, Inc.

ATM may influence autophagy through p-JNK and AMBRA1 to participate in the regulation of the HRS/IRR phenomenon. Autophagy interacts with the cellular carbon metabolite DL-Norvaline to participate in regulating the low-dose radiosensitivity of cells.

P2; Trial completion date: Mar 2022 --> Feb 2023 | Trial primary completion date: Feb 2022 --> Jan 2023

P2; Trial completion date: Oct 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Feb 2022

P2; Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: May 2020 --> Sep 2020

P2; Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Dec 2019 --> May 2020